Table 3.
Univariate analysis of temporal lobes in primary and validation cohorts.
| Characteristics | Primary cohort | P | Validation cohort | P | ||
|---|---|---|---|---|---|---|
| TLI (+) | TLI (−) | TLI (+) | TLI (−) | |||
| Sex | 0.252 | 0.469 | ||||
| Male | 51(78.5%) | 231(71.5%) | 37(71.2%) | 226(66.1%) | ||
| Female | 14(21.5%) | 92(28.5%) | 15(28.8%) | 116(33.9%) | ||
| Age(years) | 0.195 | 0.104 | ||||
| ≤60 | 62(95.4%) | 292(90.4%) | 48(92.3%) | 28(83.6%) | ||
| >60 | 3(4.6%) | 31(9.6%) | 4(7.7%) | 56(16.4%) | ||
| T stage (AJCC8th) | <0.001 | <0.001 | ||||
| T1 | 0(0%) | 17(5.3%) | 0(0%) | 18(5.3%) | ||
| T2 | 3(4.6%) | 134(41.5%) | 6(11.5%) | 131(38.3%) | ||
| T3 | 27(41.5%) | 97(30%) | 16(30.8%) | 87(25.4%) | ||
| T4 | 35(53.8%) | 75(23.2%) | 30(57.7%) | 106(31%) | ||
| N stage (AJCC8th) | 0.175 | 0.092 | ||||
| N0 | 4(6.2%) | 24(7.4%) | 1(1.9%) | 7(2%) | ||
| N1 | 18(27.7%) | 52(16.1%) | 11(21.2%) | 39(11.4%) | ||
| N2 | 37(56.9%) | 215(66.6%) | 36(69.2%) | 233(68.1%) | ||
| N3 | 6(9.2%) | 32(9.9%) | 4(7.7%) | 63(18.4%) | ||
| Hypertension | 0.69 | 0.118 | ||||
| Yes | 4(6.2%) | 16(5.0%) | 1(1.9%) | 27(7.9%) | ||
| No | 61(93.8%) | 307(95.0%) | 51(98.1%) | 315(92.1%) | ||
| Diabetes | 0.035 | 0.402 | ||||
| Yes | 6(9.2%) | 9(2.8%) | 1(1.9%) | 15(4.4%) | ||
| No | 59(90.8%) | 314(97.2%) | 51(98.1%) | 32(95.6%) | ||
| Smoking | 0.206 | 0.089 | ||||
| Yes | 30(46.2%) | 122(37.8%) | 15(28.8%) | 141(41.2%) | ||
| No | 35(53.8%) | 201(62.2%) | 37(71.2%) | 201(58.8%) | ||
| Alcoholism | 0.947 | 0.031 | ||||
| Yes | 21(32.3%) | 103(31.9%) | 6(11.5%) | 86(25.1%) | ||
| No | 44(67.7%) | 220(68.1%) | 46(88.5%) | 256(74.9%) | ||
| Cholesterol | 0.168 | 0.563 | ||||
| ≤5.2 mmol/L | 42(64.6%) | 236(73.1%) | 41(78.8%) | 25(75.1%) | ||
| >5.2 mmol/L | 23(35.4%) | 87(26.9%) | 11(21.2%) | 85(24.9%) | ||
| Triglycerides | 0.304 | 0.974 | ||||
| ≤1.7 mmol/L | 40(61.5%) | 220(68.1%) | 36(69.2%) | 236(69%) | ||
| >1.7 mmol/L | 25(38.5%) | 103(31.9%) | 16(30.8%) | 106(31%) | ||
| NLR | 0.003 | 0.273 | ||||
| ≤2.82 | 23(35.4%) | 179(55.4%) | 30(57.7%) | 22(65.5%) | ||
| >2.82 | 42(64.6%) | 144(44.6%) | 22(42.3%) | 118(34.55) | ||
| PLR | 0.892 | 0.565 | ||||
| ≤117.53 | 32(49.2%) | 16(50.2%) | 32(61.5%) | 196(57.3%) | ||
| >117.53 | 33(50.8%) | 16(49.8%) | 20(38.5%) | 146(42.7%) | ||
| Target therapy | 0.099 | 0.495 | ||||
| Yes | 16(24.6%) | 52(16.15) | 7(13.5%) | 59(17.3%) | ||
| No | 49(75.4%) | 271(83.9%) | 45(86.5%) | 28(82.7%) | ||
| ART | 0.951 | 0.886 | ||||
| Yes | 23(35.4%) | 113(35.0%) | 20(38.5%) | 12(37.4%) | ||
| No | 42(64.6%) | 210(65.0%) | 32(61.5%) | 21(62.6%) | ||